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Objective: To evaluate the safety of repeated intra-articular (IA) injections of Euﬂexxa (1% sodium
hyaluronate; IA–BioHA) for painful knee osteoarthritis (OA).
Design: Participants who completed the randomized, double-blind, 26-week FLEXX Trial comparing IA-
BioHA to IA saline (IA-SA) for knee OA1 received three weekly IA-BioHA injections in a 26-week
Extension Study. Adverse events (AEs) were recorded and the effect of treatment on knee pain was
measured immediately following a 50-foot walk test using a 100 mm visual analog scale (VAS).
Responder rate, Medical Outcomes Study Short Form 36 scores, Patient’s Global Assessment, and intake
of rescue medication were also evaluated.
Results: The Extension Study included 433 subjects, 219 who received IA-BioHA and 214 who received IA-
SA during the FLEXX Trial. Safety results from the Extension Study indicated that 43.4% (188/433) of
subjects had AEs, of which 4.8% (21/433) were deemed treatment-related AEs. Two AEs in the Extension
Study led to discontinuation, and no joint effusion was reported. Patients who continued with IA-BioHA
in the Extension Study maintained their improvement from baseline, with an average reduction in pain
in the VAS score of 3.5 mm. Patients initially treated with IA-SA in the FLEXX Trial also had a reduction
in VAS score of 9.0 mm. Secondary efﬁcacy variables also improved during the Extension Study.
Conclusions: Repeat injections of IA-BioHA were effective, safe, well tolerated, and not associated with an
increase in AEs, such as synovial effusions. Additional symptom improvements were noted for subjects
who received either IA-BioHA or IA-SA in the FLEXX Trial.
Clinical Trial Registration Number: NCT00379236
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Intra-articular (IA) injection of hyaluronate (HA) has been shown
to be safe and effective for relieving pain in patients withFerring Pharmaceuticals, Inc.,
ited States. dennis.marshall@
: Roy D. Altman, Division of
ia Los Angeles, Rehabilitation
4, United States. Tel: 1-661-
man).
s Research Society International. Posteoarthritis (OA) of the knee1e6 and is recommended for patients
who cannot be effectively managed with non-pharmacologic
interventions or simple analgesics7.
Euﬂexxa (BioHA) is a bioengineered 1% sodium HA that is
produced by biological fermentation and does not require cross-
linking8. It has a molecular weight range of 2.4e3.6 million daltons
that is achieved by controlled fermentation, recovery, and puriﬁ-
cation processes. The safety and efﬁcacy of a single course of BioHA
was evaluated in a 26-week, randomized, double-blind, multi-
center, saline-controlled FLEXX Trial1. The study included 588
subjects with painful knee OA who received three weekly IA
injections of either BioHA or buffered saline (IA-SA). Results from
the FLEXX Trial showed that IA-BioHA decreased mean painublished by Elsevier Ltd. All rights reserved.
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foot walk test by 25.7 mm vs 18.5 mm for the IA-SA group.
Both treatments were well tolerated with about 1% of subjects in
each group reporting injection-site reactions.
Although many studies support the safety and efﬁcacy of single
course IA-HA injections, fewer trials have evaluated the risks and
beneﬁts of repeated series of injections. Some evidence assessing
the safety and tolerability of repeat IA-HA injections exists from an
open-label 12-month study of 108 subjects with knee OA, in which
a second course of treatment 4e8 months after the initial inter-
vention reduced symptoms beyond that observed after the ﬁrst
course of treatment9. Another long-term study showed repeat
injections of either avian or non-avian-derived HA also improved
resting pain between the ﬁrst and tenth series of injections10.
However, 4.8% of subjects reported adverse events (AEs) (most
often pain, effusion, and erythema) for avian-derived HA vs 1.7% for
non-avian-derived HA between the second and tenth series of
injections10.One recent study suggests that re-injection with HA
may slow progression of structural damage in subjects with milder
knee OA11. Thus, it is important to understand and assess both the
risks and potential beneﬁts of repeated IA-HA injections.
To further address the safety of a repeated series of IA-BioHA
injections, we conducted a multicenter, 26-week, open-label
Extension Study of the FLEXX Trial. Subjects completing the
FLEXX Trial were offered the option to receive an additional three-
injection series (one injection per week for 3 weeks) of IA-BioHA
and were followed for an additional 23 weeks after the injections
during the Extension Study. This report provides new information
about the safety and efﬁcacy of re-injection of IA-BioHA in subjects
who received IA-BioHA in the FLEXX Trial as well as the effects of
a single series of IA-BioHA injections in the 26-week Extension
Study for subjects who received IA-SA in the FLEXX Trial.Fig. 1. Flow of participants.Subjects and methods
Summary of the FLEXX Trial
The FLEXX Trial1 was a randomized (1:1), double-blind, multi-
center, saline-controlled study that enrolled subjects with OA of the
knee according to American College of Rheumatology criteria:
moderate-to-severe joint pain (a score of 41e90 on a 100 mm VAS)
immediately following a 50-foot walk, and a bilateral standing
anterior-posterior radiograph demonstrating Kellgren and Law-
rence grade 2 or 3 OA of the target knee. Five hundred eighty-eight
(588) subjects were randomized to either IA-BioHA (n¼ 293) or IA-
SA (n ¼ 295). Two hundred ﬁfty-seven subjects (88%) who received
IA-BioHA and 259 subjects who received IA-SA (88%), a total of 516
subjects, completed the FLEXX Trial (Fig. 1).
The primary efﬁcacy endpoint of the FLEXX Trial was the
difference between IA-BioHA and IA-SA in subjects’ pain scores,
measured on a 100-mmVAS after a 50-foot walk test and compared
to baseline at 26weeks following treatment. Safety was assessed by
monitoring and reporting vital signs, physical examination of the
target knee following injection, AEs, and concomitant medications.
The sample size for the FLEXX Trial was based on the requirement
for 90% power to detect an 8.0 mm difference between average IA-
BioHA and IA-SA scores at the two-sided 5% signiﬁcance level and
an estimated 30% dropout rate by week 261.Study design for the FLEXX Trial Extension Study
The Extension Study was a multicenter open-label 26-week
trial. All 516 subjects who completed the FLEXX Trial were
eligible for the Extension Study and remained without knowledgeof whether they received IA-BioHA or IA-SA in the initial series of
injections (Fig. 1).
The FLEXX Trial Extension Study was conducted in accordance
with the ethical principles that have their origins in the Declaration
of Helsinki and in compliance with the approved protocol, Good
Clinical Practice, and applicable regulatory requirements. Consent
was obtained for participation in the Extension Study from each
subject in accordance with local Institutional Review Board
oversight.
Treatment
IA-BioHA is a 20 mg per 2 mL viscoelastic sterile solution of
highly puriﬁed, non-cross-linked, high molecular weight (2.4e3.6
million daltons) hyaluronan extracted from bacterial cells in
phosphate-buffered saline. All subjects enrolled in the Extension
Study received one 2mL injection of IA-BioHA perweek for 3weeks
in the same knee targeted during the FLEXX Trial. Skilled injectors
were instructed to cleanse the skin around the injection site with
betadine or alcohol before administering lidocaine 1% (without
epinephrine) into the skin and subcutaneous tissue. IA-BioHA was
injected by either a supra- or infra-patellar approach without
ﬂuoroscopic or ultrasound guidance. If aspiration of the joint was
necessary, the joint capsule could be inﬁltrated with lidocaine
using a 20- to 23-gauge needle. However, if an effusionwas present,
IA-BioHA was injected using a 16- to 18-gauge needle. Injections
were administered at baseline (week 26) and weeks 27 and 28.
Subjects were interviewed by telephone at week 34 or 35 and ofﬁce
visits were carried out at weeks 41 and 52 (all time points refer to
the time from initiation of the FLEXX Trial).
Table I
Characteristics of the Extension Study population
IA-BioHA/IA-BioHA
N ¼ 219
IA-SA/IA-BioHA
N ¼ 214
All N ¼ 433
Men n (%) 82 (37.4) 78 (36.4) 160
Women n (%) 137 (62.6) 136 (63.6) 273
Age Y Mean (SD) 62.7 (11.0) 60.7 (10.2) 61.7 (10.7)
Race (%)
Caucasian 170 (77.6) 163 (76.2) 333 (76.9)
African American 20 (9.1) 23 (10.7) 43 (9.9)
Asian 5 (2.3) 3 (1.4) 8 (1.8)
Hispanic 23 (10.5) 22 (10.3) 45 (10.4)
Other 1 (0.5) 3 (1.4) 4 (0.9)
Weight kg Mean (SD) 91.2 (21.8) 92.4 (22.1) 91.8 (22.0)
Height cm Mean (SD) 167.2 (11.3) 167.7 (10.9) 167.5 (11.1)
BMI kg/m2 Mean (SD) 32.7 (7.6) 33.0 (7.6) 32.8 (7.6)
SD ¼ standard deviation; BMI ¼ body mass index.
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Efﬁcacy
Efﬁcacy measures included knee pain when walking a 50-foot
distance recorded on a 100 mm VAS at Extension Study baseline
(week 26) and weeks 27, 28, 41, and 52; the Outcome Measures in
Rheumatology (OMERACT)eOsteoarthritis Research Society Inter-
national (OARSI) responder rate at Extension Study baseline and
weeks 27, 28, 41, and 5212; the Western Ontario and McMaster
Universities osteoarthritis index (WOMAC) subscales of Pain, Stiff-
ness, and Disability at Extension Study baseline and week 52;
Patient’s Global Assessment (“On the scale below, we want you to
tell us your opinion on how signiﬁcant the pain is in your knee
today. Please only comment on the knee that is receiving injections
for the trial”) recorded on a 100 mm VAS at Extension Study
baseline and week 52; the Short Form Survey Instrument SF-36v2
Health Survey (scored per instructions in the Second Edition of
the User’s Manual for the SF-36v2 Health Survey) at Extension
Study baseline and week 5213; and the weekly number of tablets of
acetaminophen rescue medication used between visits.
Safety
All AEs were recorded at each visit/interview. Safety variables
also included laboratory parameters, vital signs, and physical
examination of the knee.
Statistical methods
Efﬁcacy variables were analyzed using an intent-to-treat (ITT)
approach. The population for efﬁcacy analysis included subjects
who had an evaluation at baseline of the Extension Study (week
26), received at least one injection of IA-BioHA, and had at least one
post-baseline evaluation during the Extension Study. Safety anal-
yses included all 433 subjects enrolled in the Extension Study.
Differences in baseline characteristics between the 219 subjects
treated with IA-BioHA and the 214 subjects treated with IA-SA
during the FLEXX Trial were assessed with Chi-square tests for
categorical variables and Student’s 2-sample t-tests for continuous
variables, with or without Satterthwaite’s correction for unequal
variances, as appropriate.
Data summaries for evaluation of safety in the Extension Study
included the overall number and percentage of subjects experi-
encing at least one treatment-emergent AE (TEAE) and listing of
AEs that occurred with a prevalence of >1% in the Extension Study.
Percentages of patients experiencing TEAEs during the double-
blind trial are also included for comparison. Ninety-ﬁve percent
conﬁdence intervals (CIs) for all TEAE percentages were calculated
using the (second-order correct) Wilson interval.
For evaluation of efﬁcacy, average changes from baseline in
pain VAS scores were estimated with least squares means
(LSM) standard error of themean (SEM), derivedwith a repeated-
measures, mixed-effects analysis of covariance (ANCOVA) model,
with no data imputation for each time point. The structure of the
correlation pattern of patients repeated VAS scores of changes from
baseline is user speciﬁed. Thatwhich passed goodness-of-ﬁt criteria
resulted in using an exchangeable correlation structure (compound
symmetry) for the repeatedmeasurements. Themodel included the
following factors: baseline pain score on the 50-foot walk test, trial
center, core treatment group, trial week, and treatment group-by-
trial week interaction. The trial center was classiﬁed as a random
factor and trial week as a repeated measure. The interactions
between study center and treatment group and between the
covariate and treatment group were also to be included in the
model if they were signiﬁcant, but this was not the case for
either interaction.The other efﬁcacy outcomes of OARSIeOMERACT responder
rates, the three WOMAC domains of Pain, Stiffness, and Disability,
Patient’s Global Assessment, the average number of study-speciﬁc
acetaminophen (rescue medication) tablets consumed per week,
and SF-36 Health Survey average scores for Physical Functioning
(PF) and Bodily Pain (BP) were summarized with descriptive
statistics as changes from baseline during the Extension Study
(between week 26 and week 52) and percentage changes from the
FLEXX Trial baseline (week 0). Prior to analysis, all SF-36 itemswere
transformed into norm-based values using data from the 1988
United States general population.
Results
Subjects
Three hundred seventy-eight (378) subjects (87%) completed
the Extension Study, including 187 subjects treated with IA-SA and
191 treated with IA-BioHA in the FLEXX Trial (Fig. 1). Eleven
subjects who did not receive all three injections were included in
the group of discontinuations [study-related AEs (two), unrelated
AEs (three), withdrew consent (two), lost to follow-up (four)]. Eight
subjects failed to meet criteria for inclusion in the ITT efﬁcacy
analysis and the population evaluated for efﬁcacy thus included
425 subjects. Two of the 425 subjects in the efﬁcacy analysis
received only two injections and nine subjects received only one
injection during the Extension Study.
There were no differences in the demographics of the subjects
treated with IA-SA or IA-BioHA during the FLEXX Trial who agreed
to continue in the 26-week Extension Study (Tables I and II).
Safety
Overall, 43.4% of subjects reported at least one TEAE during the
Extension Study compared to 55.4% who reported at least one TEAE
during the double-blind FLEXX Trial (Table III). The percentages of
subjects experiencing at least one AE in the Extension Study were
similar for those who previously received IA-BioHA (43.8%) or IA-
SA (43.0%) during the FLEXX Trial. The AEs that occurred most
often in the Extension Study were arthralgia (9.9%), injury (4.4%),
nasopharyngitis (3.5%), upper respiratory infections (3%), and joint
swelling in the soft tissue at the injection site (2.3%) (Table III).
There were no differences in the AE proﬁles for subjects receiving
IA-SA as their initial injection during the FLEXX Trial or IA-BioHA
re-injection during the Extension Study (Table III).
Among subjects with at least one AE in the Extension Study, 21
(4.8%) had an event considered related to the IA-BioHA. The most
frequent treatment-related AEs were arthralgia (2.8%), joint
swelling (1.2%), peripheral edema (0.7%), and injection site pain
Table II
Discontinuation in the Extension Study
Reason for discontinuation Total N (%)
AE 13 (3.0)*
Use of exclusionary medication 3 (0.7)
Protocol violation 7 (1.6)
Withdrawal of consent 13 (3.0)
Lost to follow-up 12 (2.8)
Other 7 (1.6)
* There were two discontinuations due to TEAEs, both for arthralgia.
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synovitis or synovial effusions in either the FLEXX Trial or the
Extension Study. Twenty events classiﬁed as serious TEAEs were
reported in 12 subjects (2.8%) during the Extension Study; none
were considered related to study treatment. There were no deaths.
Two subjects re-injected with IA-BioHA had treatment-related AEs
of joint pain that led to discontinuation from the Extension Study.
Efﬁcacy
Pain VAS
At the end of the FLEXX Trial, therewas a26.5mm reduction in
pain VAS scores for subjects treated with IA-BioHA and a21.5 mmTable III
TEAEs in the Extension Study experienced by>1% of patients, with corresponding percent
FLEXX Trial
IA-BioHA
N ¼ 293
n (%)
Subjects experience at least one TEAE (any prevalence) 157 (53.6)
[47.9,59.2]
Organ-system AEs
(prevalence >1% in
Extension Study)
Gastrointestinal
disorders
Nausea 5 (1.7)
[0.7,3.9]
Diarrhea 12 (4.1)
[2.4,7.0]
General
disorders and
administrative
site
Pain 4 (1.4)
[0.5,3.5]
Injection site pain 2 (0.7)
[0.2,2.5]
Immune system
disorders
Hypersensitivity 1 (0.3)
[0.1,1.9]
Infections Nasopharyngitis 4 (1.4)
[0.5,3.5]
Upper respiratory
infection
12 (4.1)
[2.4,7.0]
Sinusitis 6 (2.1)
[0.9,4.4]
Urinary tract
infection
6 (2.1)
[0.9,4.4]
Injury and
procedural
complications
Injury 8 (2.7)
[1.4,5.3]
Musculoskeletal
and connective
tissue disorders
Arthralgia 27 (9.2)
[6.4,13.1]
Joint swelling 4 (1.4)
[0.5,3.5]
Back pain 12 (4.1)
[2.4,7.0]
Pain in extremity 3 (1.0)
[0.4,3.0]
Nervous system
disorders
Headache 6 (2.1)
[0.9,4.4]
Respiratory
disorders
Cough 7 (2.4)
[1.2,4.9]
Vascular
disorders
Hypertension 13 (4.4)
[2.6,7.4]
N¼ number of subjects in the safety population; n ¼ number of subjects having experienc
AEs categorized by the treatment arm for the double-blind trial.pain reduction in thosewho received IA-SA (Fig. 2). Subjects treated
with BioHA in the FLEXX Trial who continued into the Extension
Study had a further 3.5 mm decrease in the pain scale scores
between weeks 26 and 52. Those treated with IA-SA in the FLEXX
Trial had a further 9.0 mm decrease in pain scale scores between
weeks26and52during theExtensionStudy (Fig. 2). For bothgroups,
improvement occurred by week 27 and was sustained to week 52.
OMERACTeOARSI responder rate
Among the 425 subjects analyzed for efﬁcacy during the
Extension Study, the OMERACTeOARSI responder rate during the
FLEXX Trial (fromweek 0 to week 26) was 67% for the subjects who
received IA-BioHA and 59% for those treated with IA-SA. The
responder rate for all subjects was 75.3% at the completion of the
Extension Study (week 52) (Table IV).
WOMAC pain, stiffness, and disability
Between the end of the FLEXX Trial and the end of the Extension
Study, the mean WOMAC Pain score decreased an additional
6.1 mm, WOMAC Stiffness decreased an additional 5.9 mm, and
WOMAC Disability decreased an additional 5.6 mm. Overall
WOMAC Pain, Stiffness, and Disability scores decreased by 47.2%,
42.5%, and 44.1%, respectively, from the FLEXX Trial baseline to the
end of the Extension Study (Table IV).ages from the double-blind FLEXX Trial: number of subjects, percentages and 95% CIs
Extension Study
IA-SA
N ¼ 295
n (%)
All treatments
N ¼ 588
n (%)
IA-BioHA/
IA-BioHA
N ¼ 219
n (%)
IA-SA/
IA-BioHA
N ¼ 214
n (%)
All treatments
N ¼ 433
n (%)
169 (57.3)
[51.6,62.8]
326 (55.4)
[51.4,59.4]
96 (43.8)
[37.4,50.5]
92 (43.0)
[36.5,49.7]
188 (43.4)
[38.8,48.1]
7 (2.4)
[1.2,4.8]
12 (2.0)
[1.2,3.5]
4 (1.8)
[0.7,4.6]
3 (1.4)
[0.5,4.0]
7 (1.6)
[0.8,3.3]
2 (0.7)
[0.2,2.4]
14 (2.4)
[1.4,4.0]
3 (1.4)
[0.5,4.0]
1 (0.5)
[0.1,2.6]
4 (0.9)
[0.4,2.4]
1 (0.3)
[0.1,1.9]
5 (0.9)
[0.4,2.0]
4 (1.8)
[0.7,4.6]
1 (0.5)
[0.1,2.6]
5 (1.2)
[0.5,2.7]
0
[0.0,1.3]
2 (0.3)
[0.1,1.2]
0
[0.0,1.7]
3 (1.4)
[0.5,4.0]
3 (0.7)
[0.2,2.0]
1 (0.3)
[0.1,1.9]
2 (0.3)
[0.1,1.2]
3 (1.4)
[0.5,4.0]
1 (0.5)
[0.1,2.6]
4 (0.9)
[0.4,2.4]
13 (4.4)
[2.6,7.4]
17 (2.9)
[1.8,4.6]
10 (4.6)
[2.5,8.2]
5 (2.3)
[1.0,5.4]
15 (3.5)
[2.1,5.6]
11 (3.7)
[2.1,6.6]
23 (3.9)
[2.6,5.8]
6 (2.7)
[1.3,5.9]
7 (3.3)
[1.6,6.6]
13 (3.0)
[1.8,5.1]
10 (3.4)
[1.9,6.1]
16 (2.7)
[1.7,4.4]
5 (2.3)
[1.0,5.2]
3 (1.4)
[0.5,4.0]
8 (1.9)
[0.9,3.6]
6 (2.0)
[0.9,4.4]
12 (2.0)
[1.2,3.5]
3 (1.4)
[0.5,4.0]
1 (0.5)
[0.1,2.6]
4 (0.9)
[0.4,2.4]
9 (3.1)
[1.6,5.7]
17 (2.9)
[1.8,4.6]
9 (4.1)
[2.2,7.6]
10 (4.7)
[2.6,8.4]
19 (4.4)
[2.8,6.8]
35 (11.9)
[8.7,16.1]
62 (10.5)
[8.3,13.3]
19 (8.7)
[5.6,13.2]
24 (11.2)
[7.7,16.1]
43 (9.9)
[7.5,13.1]
3 (1.0)
[0.4,3.0]
7 (1.2)
[0.6,2.4]
6 (2.7)
[1.3,5.9]
4 (1.9)
[0.7,4.7]
10 (2.3)
[1.3,4.2]
11 (3.7)
[2.1,6.6]
23 (3.9)
[2.6,5.8]
6 (2.7)
[1.3,5.9]
1 (0.5)
[0.1,2.6]
7 (1.6)
[0.8,3.3]
10 (3.4)
[1.9,6.1]
13 (2.2)
[1.3,3.8]
3 (1.4)
[0.5,4.0]
4 (1.9)
[0.7,4.7]
7 (1.6)
[0.8,3.3]
11 (3.7)
[2.1,6.6]
17 (2.9)
[1.8,4.6]
3 (1.4)
[0.5,4.0]
2 (0.9)
[0.3,3.3]
5 (1.2)
[0.5,2.7]
3 (1.0)
[0.4,3.0]
10 (1.7)
[0.9,3.1]
3 (1.4)
[0.5,4.0]
1 (0.5)
[0.1,2.6]
4 (0.9)
[0.4,2.4]
5 (1.7)
[0.7,3.9]
18 (3.1)
[1.9,4.8]
1 (0.5)
[0.1,2.5]
4 (1.9)
[0.7,4.7]
5 (1.2)
[0.5,2.7]
ed the TEAE within the organ system class; (%)¼ percentage of subjects ¼ (n/N) 100.
Fig. 2. Mean change in VAS pain scores following 50-foot walk test from week 0 to
week 52.
During the FLEXX Trial, the randomized groups received one injection of either IA-
BioHA or IA-SA at weeks 0, 1 and 2, with re-injection of IA-BioHA at weeks 26, 27,
and 28 only in subjects who elected to participate in the Extension Study. Data points
represent LSM  SEM, estimated with a repeated-measures, mixed-model ANCOVA
model, with no data imputation. The model included the following factors: baseline
pain score on the 50-foot walk test as a covariate, trial center, core treatment group,
trial week, and treatment group-by-trial week interaction. Trial center was classiﬁed as
a random factor, and trial week as a repeated measure.
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Patient’s Global Assessment improved an additional 8.1 mm,
an overall 51.6% decrease from initiation of the FLEXX Trial to the
end of the Extension Study.
Use of rescue medication
Mean acetaminophen use was reduced from 14.6 to 12.8 tablets
per week over the course of the FLEXX Trial. At the end of the
Extension Study, acetaminophen use was further reduced to 9.5
tablets per week, representing an overall 34.9% reduction from the
beginning of the FLEXX Trial (Table IV).
SF-36
At FLEXX Trial baseline, the mean SF-36 PF and BP scale scores
were 32.7 and 36.9, respectively. At the end of the FLEXX Trial,
these scores improved to 36.7 and 40.4. At the end of the Extension
Study, the scores for the PF and BP scales were 37.7 and 42.7. The
mean changes from the end of the FLEXX Trial to the end of the
Extension Study were 0.9 and 2.2 for SF-36 PF and BP, respectively.
From FLEXX Trial baseline to the end of the Extension Study, there
were 15.2% and 15.7% improvements for SF-36 PF and BP,
respectively.Table IV
Summary of results for secondary efﬁcacy endpoints
OMERACTeOARSI Responders (%) 75.3
Measure % Improvement from Baseline
of Double-blind Study
WOMAC Pain 47.2
WOMAC Stiffness 42.0
WOMAC Disability 44.1
Patient’s Global Assessment 51.6
Acetaminophen use 34.9 (reduction)
SF-36 PF 15.2
SF-36 BP 15.7Discussion
Although efﬁcacy of IA-HA injections has been established
previously, safety of repeated HA injections, including BioHA, is
understudied. The FLEXX Trial Extension Study showed that
a repeated series of three weekly injections of IA-BioHA given
23 weeks after an initial three-injection treatment course was
effective, safe, andwell tolerated in subjectswith chronic painful OA
of the knee. Pain reduction observed from an initial injection of IA-
BioHA during the FLEXX Trial was sustained for an additional
23weeks during the Extension Studyafter IA-BioHA re-injection. No
subject reported a joint effusion during either the initial FLEXX Trial
or following re-injection of IA-BioHA during the Extension Study.
The positive results obtainedwith re-injection of IA-BioHA in the
present study are consistent with those from prior trials that have
addressed this issue. An observational study of 108 subjects with
knee OA showed decreased pain in four subjects who received
a repeat series of ﬁve injections of HA9. Another study of 306
subjects with knee OAwho received four series of ﬁve HA injections
every 6 months indicated that HA was signiﬁcantly superior to
saline with respect to achievement of OARSI responder criteria over
3.5 years of follow-up14. A third study, which included 897 subjects
with knee OAwho received two series of a 500,000e730,000 dalton
non-avian-derived HA, showed that improvements in walking and
resting pain following the second series of injections were at least
equivalent to those after the ﬁrst series15. Safety results and AEs
associated with HA re-injection were not reported in these studies.
Some data regarding safety of repeated HA injections have been
reported previously. Results of one small-scale study of 39 subjects
with knee OA who received a series of three injections with either
saline or HA every 3 months over 1 year indicated that HA re-
injection was not signiﬁcantly superior to placebo for improving
pain or function. In this trial, 40% of the 20 HA-treated subjects
reported pain during or immediately after the injection for at least
one of the nine injections for a total of 17 events16. A trial of 75
subjects with knee OA treated with a three-injection series of
a straight chain avian-derived HA every 6 months for 30 months
showed that pain decreased following the ﬁrst injection and
continued to decline throughout the study. Neither local nor
systemic AEs were observed with re-injection; however, ﬁve
subjects (6.6%) complained of localized pain after IA injection17.
Several published studies report differences in AE risk associated
with hylan and different HA preparations. A systematic review and
meta-analysis of thirteen randomized, controlled clinical trials with
a pooled total of 2085 patients revealed an increased risk associated
with hylan for any local AE (relative risk [RR] 1.91; 95% CI 1.04, 3.49;
I ¼ 28%) and for ﬂares (RR 2.04; 95% CI 1.18, 3.53; I ¼ 0%), however
there was no difference observed in efﬁcacy for hylan and HAs18.
One multicenter, subject-blinded, randomized control trial
included 660 subjects with symptomatic knee OA who were
randomized to three IA injections of either a high molecular weight
(average molecular weight 6 million daltons) avian-derived, cross-
linked hylan or one of two HA preparations; a non-cross-linked
medium molecular weight (1.0e2.9 million daltons) avian-derived
HA or a non-cross-linked low molecular weight (about 1.5 million
daltons) HA obtained through bacterial fermentation. Subjects
completing the initial phase of the trial were offered an additional
three-injection series during months 7e12 of the study. Although
pain relief was similar in all treatment groups, re-injection of the
high molecular weight, cross-linked, avian-derived hylan was
associated with more local AEs (9.1%), effusions (7.3%), and ﬂares
(6.4%) than the HA preparations (2.7%, 2.7%, and 0%, respectively)2.
Repeated injections of avian and non-avian-derived HA were also
compared in a non-randomized study that included 4412 subjects
treated over the period from 1997 to 2007. The HA preparation used
R.D. Altman et al. / Osteoarthritis and Cartilage 19 (2011) 1169e11751174was based on subject preference and subsequent series of injections
were at the subjects’ discretion. Study results indicated that both
the avian and non-avian preparations improved resting pain over as
many as 10 series of injections. AEs were reported for 4.8% of
subjects receiving avian-derived HA vs 1.7% for those treated with
the non-avian preparation10.
Although the FLEXX Trial Extension Study provided new infor-
mation about the safety and efﬁcacy of BioHA re-injection, the trial
had limitations that should be acknowledged. The Extension Study
was an open-label trial and lacked a control group. This aspect of
the study design may have inﬂuenced subjects’ perceptions and
reporting of efﬁcacy, but it was necessary to maintain subject
participation, as it is very difﬁcult to enroll subjects in a long-term
study if they are not guaranteed active therapy. The open-label
design of the Extension Study was unlikely to have inﬂuenced AE
reporting, especially since the subjects remained blinded to
previous therapy, and subjects from both the IA-SA and IA-BioHA
treated groups reported similar numbers of AEs. A second limita-
tion of the Extension Study was that it included only a single course
of retreatment. Thus, it is not known whether further series of re-
injections would result in different efﬁcacy or safety ﬁndings.
Finally, while the sample size for this trial was large relative to
several of the other long-term evaluations of repeated injections of
IA-HA, conclusions regarding safety must be tempered. With
sample sizes of 200, 300, and 400, for example, there is 95% chance
of observing at least one event with rates of 1.5%, 1% and 0.75%,
respectively. Detection of very rare AEs would require study of
many thousands of subjects19.
In conclusion, results from this FLEXX Trial Extension Study
showed that re-injection with BioHA was safe and effective.
Comparison of Extension Study results with those from prior trials
suggests further that the efﬁcacy of IA-BioHA re-injection was at
least equivalent to that reported for re-injection of other IA-HA
agents, and that the AE proﬁle for re-injection of IA-BioHA was at
least equal, if not superior, to that reported for other IA-HA prep-
arations. Results from subjects who received their initial treatment
with IA-BioHA in the FLEXX Trail Extension Study also supported
the efﬁcacy and safety of this preparation.
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